HYMPAVZI® Receives Expanded Indication from FDA

The new indication for HYMPAVZI^® (marstacimab-hncq) broadens access to this once-weekly non-factor prophylactic therapy that targets TFPI to improve clotting and reduce bleeding episodes. It now can be prescribed for people with hemophilia A or B with inhibitors ages 12 years and older with inhibitors, and pediatric patients ages 6-11 years with hemophilia A and B with or without inhibitors.

Source: National Bleeding Disorders Foundation, NBDF Notes, July 2026